RT Journal Article
T1 Deciphering Multiple Sclerosis Progression.
A1 Meca-Lallana, Virginia
A1 Berenguer-Ruiz, Leticia
A1 Carreres-Polo, Joan
A1 Eichau-Madueño, Sara
A1 Ferrer-Lozano, Jaime
A1 Forero, Lucía
A1 Higueras, Yolanda
A1 Téllez Lara, Nieves
A1 Vidal-Jordana, Angela
A1 Pérez-Miralles, Francisco Carlos
K1 MRI
K1 multiple sclerosis
K1 neurodegeneration
K1 neurofilament
K1 progressive multiple sclerosis
AB Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central nervous system, triggered by unknown environmental factors in patients with predisposing genetic risk profiles. The prevention of neurological disability is one of the essential goals to be achieved in a patient with MS. However, the pathogenic mechanisms driving the progressive phase of the disease remain unknown. It was described that the pathophysiological mechanisms associated with disease progression are present from disease onset. In daily practice, there is a lack of clinical, radiological, or biological markers that favor an early detection of the disease's progression. Different definitions of disability progression were used in clinical trials. According to the most descriptive, progression was defined as a minimum increase in the Expanded Disability Status Scale (EDSS) of 1.5, 1.0, or 0.5 from a baseline level of 0, 1.0-5.0, and 5.5, respectively. Nevertheless, the EDSS is not the most sensitive scale to assess progression, and there is no consensus regarding any specific diagnostic criteria for disability progression. This review document discusses the current pathophysiological concepts associated with MS progression, the different measurement strategies, the biomarkers associated with disability progression, and the available pharmacologic therapeutic approaches.
SN 1664-2295
YR 2021
FD 2021-04-07
LK http://hdl.handle.net/10668/17631
UL http://hdl.handle.net/10668/17631
LA en
DS RISalud
RD Apr 19, 2025